Magavern, E. F.
Kaski, J. C. http://orcid.org/0000-0001-8068-0189
Turner, R. M.
Janmohamed, A.
Borry, P.
Pirmohamed, M.
Article History
Accepted: 19 January 2021
First Online: 2 February 2021
Declarations
:
: This article does not contain any studies with human participants performed by any of the authors.
: MP receives research funding from various organisations including the MRC, NIHR, EU Commission, HDR UK, and Health Education England. He has also received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly, and Novartis); a PhD studentship jointly funded by EPSRC and AstraZeneca; and grant funding from Vistagen Therapeutics. He has also unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. None of the funding declared above has been used for the current paper. The other authors declare no conflict of interest.
Free to read: This content has been made available to all.